ClinicalTrials.gg
CompletedNCT00548301Updated Jul 1, 2011

Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-007)

A Phase 3 interventional study of cyclosporine in Dry Eye Syndromes, sponsored by Sirion Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-01.

Sponsored by Sirion Therapeutics, Inc. · Phase 3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.

Phase 3
7 of 45
none open now
Registered
6th of 45
by date
Lead sponsor
3 of 45
Sirion Therapeutics, Inc.

Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is one of 7 in phase 3, and was the 6th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing cyclosporine in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The purpose of this phase 3 study is to determine the safety and efficacy of cyclosporine in the treatment of dry eye syndrome.

03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of moderate to severe dry eye syndrome with or without Sjogren's syndrome or other disease

Exclusion criteria

Exclusion Criteria:

  • Intraocular or refractive surgery in the study eye within 3 months prior to study start
  • Unwilling to discontinue use of contact lenses during the run-in and duration of the study
  • Pregnancy or lactation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double

Interventions

06

Study locations

1 site
  • Eye Center Northeast
    Bangor, Maine 04401, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00548301
Lead sponsor
Sirion Therapeutics, Inc.
First posted
Oct 23, 2007
Last update
Jul 1, 2011

Study contacts

Roger Vogel, MD
study chair · Sirion Therapeutics
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion